Duke Street Bio Ltd. has divulged poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Personalized Medicine. 2015;12(2):139-154. Compared to AstraZeneca, the other pharmaceutical companies have fewer Phase III trials running for their compounds. However, the approaches within these ...

Scientists at St. John’s University, The University of Pennsylvania and Université de Montréal have identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the ...

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer. Results from the PAOLA-1 study showed ...

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

With a PhD in Genetics and Genomics, Niki Spahich channels her infectious disease research and science communication experiences into her role as the manager of The Scientist's Creative Services team.

“With our recently implemented trial protocol, we expect to initiate patient enrollment soon and further investigate stenoparib’s dual mechanisms of action—both as a PARP inhibitor and as a ...

Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...